• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Left atrial appendage closure is safe and effective in atrial fibrillation

byAlex XiangandSimon Pan
January 13, 2026
in Cardiology, Chronic Disease, Imaging and Intervention
Reading Time: 2 mins read
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Share on FacebookShare on Twitter

1. Left atrial appendage closure (LAAC) was well tolerated and may be considered as an alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation refusing oral anticoagulation.

Evidence Rating Level: 2 (Good)

While OAC remains the first-line prevention therapy of ischemic stroke in patients with atrial fibrillation, patients sometimes refuse it despite medical advice due to concerns of bleeding risk or opposition to chronic use of medications. Left atrial appendage closure (LAAC) is a minimally invasive procedure that excludes the left atrial appendage from systemic circulation to reduce the risk of thromboembolism. LAAC is recommended for patients with contraindications to long-term anticoagulation and has been shown to be non-inferior to vitamin-K antagonists in preventing stroke. This retrospective, multicenter, observational cohort study therefore sought to compare the safety and efficacy of LAAC with OAC in patients with atrial fibrillation. 2649 patients with atrial fibrillation who underwent LAAC were initially screened to identify 119 patients who received the intervention due to OAC refusal and compared with a control group of 238 patients. The rate of procedural complications did not differ significantly between the two groups (1.7% versus 4.6%; adjusted risk ratio: 0.56; 95% CI, 0.13–2.43; P=0.440). At 3 years, the composite of cardiovascular death, stroke, or systemic embolism was significantly lower in the refusal group (adjHR, 0.37 [95% CI, 0.14–0.99]; P=0.048). This may be explained by the finding that refusal patients were significantly younger (68.1±10.1 versus 75.0±8.6; P <0.001) and had significantly fewer comorbidities, including hypertension, diabetes, and chronic kidney dysfunction. These results suggest LAAC might be considered as an alternative to oral anticoagulation for stroke prevention in patients who are rigidly drug adverse. However, larger, randomized trials are required to provide a definitive answer about non-inferiority.

Click here to read this study in Journal of the American Heart Association

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Chronic exposure to particulate matter is associated with increased cardiovascular risk

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

2 Minute Medicine Rewind September 7, 2026

Tags: #oral anticoagulationacute strokeatrial fibrillationcardiologyLeft atrial appendage closure
Previous Post

Lilly unveils TuneLab AI platform for biotechs

Next Post

CASPer Exam: Transforming Medical School Admissions

RelatedReports

Cardiology

Chronic exposure to particulate matter is associated with increased cardiovascular risk

September 10, 2026
Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
Long-term outcomes for off-pump and on-pump CABG are similar
Weekly Rewinds

2 Minute Medicine Rewind September 7, 2026

September 7, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

September 4, 2026
Next Post
A collection of symbolic items such as a microscope

CASPer Exam: Transforming Medical School Admissions

Children’s hospital visits for suicide ideation and attempts are increasing

Use of ammoxetine is safe and effective in adults with major depressive disorder

Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults

DAWN Trial: Redefining the Treatment Window for Stroke Thrombectomy

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Daraxonrasib extends survival in metastatic pancreatic cancer
  • Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being
  • A lower threshold for referral to the emergency department for outpatient hyperkalemia may reduce mortality
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.